| Company Name: |
Molsyns Research
|
| Tel: |
+91-9586858886 +91-9586858886 |
| Email: |
info@molsyns.com |
| Products Intro: |
Product Name:Abiraterone Isopropyl Ether
CAS:2484719-15-3
Purity:98% Package:25mg; 50mg;100mg and 1 g
|
| Company Name: |
Beijing Comparison Pharmaceutical Technology Co., Ltd
|
| Tel: |
010-010-52878169 15801002657 |
| Email: |
sales@bjcomparison.com |
| Products Intro: |
Product Name:3-((3S,8R,9S,10R,13S,14S)-3-isopropoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)pyridine
CAS:2484719-15-3
Purity:≥95% Package:100mg/;50mg/;25mg/;10mg/
|
|
| | Pyridine, 3-[3-(1-methylethoxy)androsta-5,16-dien-17-yl]- Basic information |
| Product Name: | Pyridine, 3-[3-(1-methylethoxy)androsta-5,16-dien-17-yl]- | | Synonyms: | Pyridine, 3-[3-(1-methylethoxy)androsta-5,16-dien-17-yl]-;Abiraterone impurities426;Abiraterone Impurity 08;Abiraterone Isopropyl EtherQ: What is
Abiraterone Isopropyl Ether Q: What is the CAS Number of
Abiraterone Isopropyl Ether;3-[(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-3-propan-2-yloxy-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-17-yl]pyridine;(3β,5β,6β)-5,6-epoxy-17-(3-pyridinyl)-Androst-16-en-3-ol;Acetic acid abiolone impurity 4 | | CAS: | 2484719-15-3 | | MF: | C27H37NO | | MW: | 391.59 | | EINECS: | | | Product Categories: | | | Mol File: | 2484719-15-3.mol | ![Pyridine, 3-[3-(1-methylethoxy)androsta-5,16-dien-17-yl]- Structure](CAS/20210111/GIF/2484719-15-3.gif) |
| | Pyridine, 3-[3-(1-methylethoxy)androsta-5,16-dien-17-yl]- Chemical Properties |
| Boiling point | 501.6±50.0 °C(Predicted) | | density | 1.07±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | Chloroform (Slightly), Methanol (Slightly) | | pka | 5.31±0.12(Predicted) | | form | Solid | | color | White to Off-White |
| | Pyridine, 3-[3-(1-methylethoxy)androsta-5,16-dien-17-yl]- Usage And Synthesis |
| Uses | Abiraterone Isopropyl Ether is an impurity of Abiraterone (A108490), a steroidal cytochrome P 450 17a-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer. |
| | Pyridine, 3-[3-(1-methylethoxy)androsta-5,16-dien-17-yl]- Preparation Products And Raw materials |
|